Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $233.6 million.

  • Vanda Pharmaceuticals' Non-Current Assets rose 983.23% to $233.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $904.8 million, marking a year-over-year increase of 599.05%. This contributed to the annual value of $217.3 million for FY2024, which is 84.46% up from last year.
  • Vanda Pharmaceuticals' Non-Current Assets amounted to $233.6 million in Q3 2025, which was up 983.23% from $229.8 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Non-Current Assets peaked at $233.6 million during Q3 2025, and registered a low of $105.0 million during Q3 2023.
  • Its 5-year average for Non-Current Assets is $158.5 million, with a median of $121.0 million in 2021.
  • In the last 5 years, Vanda Pharmaceuticals' Non-Current Assets plummeted by 875.4% in 2022 and then surged by 10253.44% in 2024.
  • Vanda Pharmaceuticals' Non-Current Assets (Quarter) stood at $115.5 million in 2021, then fell by 0.46% to $115.0 million in 2022, then skyrocketed by 87.46% to $215.5 million in 2023, then grew by 0.84% to $217.3 million in 2024, then rose by 7.51% to $233.6 million in 2025.
  • Its Non-Current Assets was $233.6 million in Q3 2025, compared to $229.8 million in Q2 2025 and $224.0 million in Q1 2025.